{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:04:32Z","timestamp":1785359072300,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ophtha.2026.06.030","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:44:38Z","timestamp":1783352678000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Five-Year Risks of Systemic Complications with Biologic versus Conventional Therapy in Noninfectious Uveitis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-7089","authenticated-orcid":false,"given":"Muhammad Z.","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2830-9832","authenticated-orcid":false,"given":"Jawad","family":"Muayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Surgent-Nahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Shakoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-5770","authenticated-orcid":false,"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed B.","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ophtha.2026.06.030_bib1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of noninfectious uveitis in the United States: a claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2026.06.030_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archopht.1962.00960030506014","article-title":"Epidemiology of uveitis: incidence and prevalence in a small urban community","volume":"68","author":"Darrell","year":"1962","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2026.06.030_bib3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.06.030_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2024.1412930","article-title":"Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond","volume":"4","author":"Chauhan","year":"2024","journal-title":"Front Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2026.06.030_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2352019","article-title":"Use of corticosteroids in non-infectious uveitis\u2013expert consensus in Taiwan","volume":"56","author":"Chang","year":"2024","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.ophtha.2026.06.030_bib6","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/MS9.0000000000000546","article-title":"Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal","volume":"85","author":"Sharma","year":"2023","journal-title":"Ann Med Surg"},{"issue":"5","key":"10.1016\/j.ophtha.2026.06.030_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2026.06.030_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ophtha.2026.06.030_bib9","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2026.06.030_bib10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2026.06.030_bib11","first-page":"3209","article-title":"Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate, posterior and panuveitis: 54 month results of The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study","volume":"56","author":"Kempen","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"19","key":"10.1016\/j.ophtha.2026.06.030_bib12","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"Kempen","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ophtha.2026.06.030_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jama.2025.4358","article-title":"Uveitis in adults: a review","volume":"334","author":"Maghsoudlou","year":"2025","journal-title":"JAMA"},{"issue":"10050","key":"10.1016\/j.ophtha.2026.06.030_bib14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ophtha.2026.06.030_bib15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ophtha.2026.06.030_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","article-title":"Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"128","author":"Suhler","year":"2021","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2026.06.030_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ophtha.2026.02.020","article-title":"Tumor necrosis factor-\u03b1 inhibition and the unmasking of CNS demyelination across a large US health research network","volume":"133","author":"Muayad","year":"2026","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2026.06.030_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.ophtha.2026.06.030_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1046306","article-title":"Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: a systematic review","volume":"14","author":"Jahnich","year":"2023","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.ophtha.2026.06.030_bib20","doi-asserted-by":"crossref","first-page":"e1S","DOI":"10.1378\/chest.12-1044","article-title":"Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"142","author":"Baughman","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ophtha.2026.06.030_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1470-2045(23)00524-7","article-title":"Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials","volume":"25","author":"Fujiwara","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ophtha.2026.06.030_bib22","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short-and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.ophtha.2026.06.030_bib23","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.14309\/ajg.0000000000003541","article-title":"ACG clinical guideline update: preventive care in inflammatory bowel disease","volume":"120","author":"Farraye","year":"2025","journal-title":"Am J Gastroenterol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026004641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026004641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:43:03Z","timestamp":1785357783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026004641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S0161642026004641"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.06.030","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Five-Year Risks of Systemic Complications with Biologic versus Conventional Therapy in Noninfectious Uveitis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}